Final report 

A summary of the final report of results achieved is being published in the homepage.   

End of the project

After 3 years of commitment, the  project is now concluded.

The group is describing the results achieved to be submitted to the European Commission.  

Relevant information describing what has been done will appear on the homepage of this website, in the next few days. 

General Assembly and scientific meeting, Amsterdam VU University

On Sept 30 and Oct 1, 2010 the Consortium had  its the last scientific meeting. It was the opportunity to revise in details and agree the work programme for the few months of research left.

Most of deliverables and milestones foreseen at application will be met; the few changes occurred will not affect the overall result.

Accordinlgy,  it was decided no to postpone the end of the project.

Second internal progress review at May 2010

 Again time for an internal exercise to monitor the progress of the project and the use of resources (after the first one carried out in December 2008).

And once more the confirmation for all groups that they are in track with sound perspective to deliver what promised.

EC approval of first reporting

After the first official reporting, the European Commission informs that on the basis of the evidence submitted and the evaluation of results obtained up to Sept 30, 2010, the research may continue.

The overall assessment of the reviewers was flattering "excellent progress". 

Annual General Assembly and Scientific Meeting, Zurich, Campus Hoggerberg Oct 1-2, 2009 

"The project so far is in track and potentially will deliver more than planned, thanks to the commitment of all groups". This is the conclusion of the meeting held in Zürich, Switzerland thanks to Prof Dario Neri, Adamant Steering Committee member, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology.    

The meeting was attended by an Advisory Board member  Prof Begent, Professor of Oncology, UCL Cancer Institute, University College of London, UK Advisory Board, who described the achievements of the group simply as important.  

The group will continue its work with renewed enthusiasm and will strengthen the ongoing cooperations.

General Assembly and Scientific meeting Universite de Liège, Chȃteau de Colonster, Belgium Febr 19-20, 2009             

The Consortium met in Belgium at the  Université de Liège thanks to the hospitality of prof Vincent Castronovo,  Faculté de Médécine, Laboratiore de Recherche sur les Metastases. 

One more time the scientific  progress of the project was the major object of the meeting.  Scientific presentations of the data so far achieved by all the scientist-partners enabled a global discussion.   

The assessment of the progress was  positive: in particular neither delays, nor major deviations from the planned tasks were present. 

The conclusion was to continue on this track.

Annual General Assembly and Scientific Meeting

The ADAMANT Consortium is convening in Liège, Belgium, for a scientific meeting and a General Assembly.

First 9-month interim internal progress review 

The beginning of the year for the  ADAMANT Consortium  started with the results of the first internal assessment of the scientific progress of the project. 

In December, all the partners  described the progress done in the first nine months of the project (April –December 2008). They also had a careful look at their budgets and analyze if they were in track from a financial point of view.    

A first assessment of the results so far was carried out by the Coordinator, Dr Raffaella Giavazzi, Mario Negri Institute for Pharmacological Research, with the assistance of the Steering Committee members, Prof Dario Neri,  Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology,  Zürich, Switzerland, and Prof Guus Van Dongen, Laboratory for Tumor Biology, Department of Otolaryngology, VU medical Center, De Vereniging voor Christelijk Wetenschappelijk Onderwijs, Amsterdam, The Netherlands.  

The scientific progress  was assessed as consistent with objectives and schedule agreed with the European Commission at the time of funding under FP7.  A good start for a promising year.

ADAMANT Kick off meeting

Today we hold the kick off meeting of the ADAMANT project at the Mario Negri Institute for Pharmacological Research, Milan, Italy, with a plenary participation from  all the groups of research involved.  

The meeting will focus on detailed presentations of individual scientific contributions to the project from all participating labs through their Principal Investigators.   

A short overview of some management issues is also foreseen, such as the decision about the Advisory Board, how to assess the project progress at intermediate intervals before the official reporting to the European Commission, a decision regarding  forthcoming meetings.  

Administrative and organizational tasks will be kept to a minimum to concentrate resources and efforts to the scientific research, the core business of the project.   

The project ADAMANT commences today its activity to discover improved anticancer therapies

Nine organizations from six European countries - comprising research institutes, universities, hospitals, foundations and small enterprises - today signed a three-year € 3,000,000 research contract with the European Commission.